Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical…
Today's Pre-Market Ripper List $ADMA, $ALGM, $AMRX, $BKSY, $ICHR, $KLAC, $NVDA, $PG, $PM, $Q, $QGEN, $TER https://t.co/HvfHDomAeG
7 analysts rate AMRX Buy on consensus.
Consensus price target: $22.71 (+13.3% upside from $20.05)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Kiely John director | Aug 13, 2026 | Sale | 50,000 | $882K |
| Daly Jason B. EVP, Chief Legal Officer | Aug 12, 2026 | Sale | 210,000 | $3.65M |
| Shah Nikita Executive Vice President | Aug 12, 2026 | Sale | 146,403 | $2.56M |
| Daly Jason B. EVP, Chief Legal Officer | Aug 11, 2026 | Sale | 6,613 | $117.05K |
| Autor Deborah M. director | May 11, 2026 | Sale | 34,819 | $450.56K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $3.02B | +8.05% | $72.06M |
| 2024 | $2.79B | +16.73% | $-116.89M |
| 2023 | $2.39B | +8.2% | $-83.99M |
Stock data for AMRX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics